Comment "Are the aims of the K/DOQI guidelines for mineral metabolism disorders in predialysis chronic kidney failure unachievable or inadequate?"

被引：0
|
作者：
Negri, Armando L. [1 ]
机构：
[1] Univ Salvador, Serv Nefrol, Inst Invest Metab, Buenos Aires, DF, Argentina
来源：
NEFROLOGIA | 2013年 / 33卷 / 03期
关键词：
D O I：
10.3265/Nefrologia.pre2013.Apr.11941
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：424 / 424
页数：1
相关论文
共 50 条
  • [31] Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients
    Monge, Matthieu
    Shahapuni, Irina
    Oprisiu, Roxana
    El Esper, Najeh
    Moriniere, Philippe
    Massy, Ziad
    Choukroun, Gabriel
    Fournier, Albert
    NATURE CLINICAL PRACTICE NEPHROLOGY, 2006, 2 (06): : 326 - 336
  • [32] Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients
    Matthieu Monge
    Irina Shahapuni
    Roxana Oprisiu
    Najeh El Esper
    Philippe Morinière
    Ziad Massy
    Gabriel Choukroun
    Albert Fournier
    Nature Clinical Practice Nephrology, 2006, 2 : 326 - 336
  • [33] K/DOQI practice guidelines for bone metabolism and disease in chronic kidney disease: Another opportunity for renal dietitians to take a leadership role in improving outcomes for patients with chronic kidney disease
    McCann, L
    JOURNAL OF RENAL NUTRITION, 2005, 15 (02) : 265 - 274
  • [34] The National Kidney Foundation K/DOQI clinical practice guidelines for dietary protein intake for chronic dialysis patients
    Kopple, JD
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) : S68 - S73
  • [35] Association of the K/DOQI classification system of chronic kidney disease and mortality in a heart failure population.
    Khan, NA
    Ma, IW
    Thompson, C
    Humphries, K
    Salem, D
    Samak, MJ
    Adeera, L
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2005, 20 : 83 - 84
  • [36] K-DOQI guidelines for calcium and phosphorus metabolism in cronic kidney disease: outcomes, compliance and new drugs for treatment
    Negri, A. L.
    NEFROLOGIA, 2007, 27 (06): : 670 - +
  • [37] FIBROBLAST GROWTH FACTOR 23 AS AN EARLY MARKER OF MINERAL AND BONE DISORDERS IN PREDIALYSIS CHRONIC KIDNEY DISEASE PATIENTS
    Martynyuk, Liliya
    Mariana, Chaikovska
    Sergii, Butvyn
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [38] K/DOQI GUIDELINES ATTAINMENT OF BONE AND MINERAL METABOLISM MARKERS AND RELATIONSHIP WITH HEALTH-RELATED QUALITY OF LIFE IN HEMODIALYSIS PATIENTS
    Gelev, S.
    Spasovski, G.
    Mladenovska, D.
    Trajceska, L.
    Andreevska-Severova, G.
    Selim, G.
    Sikole, A.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2011, 34 (08): : 675 - 675
  • [39] TO WHAT EXTENT CAN WE ACHIEVE MINERAL BONE METABOLISM TREATMENT TARGETS AS SUGGESTED BY UPDATED 2017 KDIGO GUIDELINES IN PATIENTS WITH PREDIALYSIS CHRONIC KIDNEY DISEASE
    Dincer, Mevlut Tamer
    Ozcan, Eyda Gul
    Alagoz, Selma
    Karaca, Cebrail
    Gulcicek, Sibel
    Trabulus, Sinan
    Pekpak, Meltem
    Seyahi, Nurhan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1212 - 1212
  • [40] Spanish nephrologists and the management of mineral and bone metabolism disorders in chronic kidney disease
    Cannata-Andia, Jorge
    Vicente Torregrosa, J.
    NEFROLOGIA, 2014, 34 (02): : 175 - 188
12345